Bevacizumab: Difference between revisions
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
* Marketed By: Genentech & Roche<br /> | * Marketed By: Genentech & Roche<br /> | ||
* Major Indication: Colorectal [[Cancer]]<br /> | * Major Indication: Colorectal [[Cancer]]<br /> | ||
* Drug Class: [[ | * Drug Class: [[Vascular Endothelial Growth Factor]] Inhibitor - [[Monoclonal Antibody]] | ||
* Date of FDA Approval (Patent Expiration): 2004 ( | * Date of FDA Approval (Patent Expiration): 2004 ( | ||
* 2009 Sales: $4.8 Billion<ref>Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)</ref> | * 2009 Sales: $4.8 Billion<ref>Irena Melnikova, Therapies for Alzheimer's disease, Nature Reviews Drug Discovery 6, 341-342 (May 2007)</ref> | ||